Fate Therapeutics Q2 net loss narrows to $30.2M; first patient dosed in lupus nephritis registrational trial

FATE THERAPEUTICS INC

2026-Q2 EPS reported -$0.51 revenue$3,381,000

Net loss $30.2M ($0.25/share) vs $34.1M ($0.29/share) in Q2 2025; revenue $2.1M from Ono collaboration.
Cash $153.8M at June 30, down $21M in quarter; runway expected into 2028.
First patient dosed in RECLAIM-LN Phase 2 registrational trial for lupus nephritis with FT819; outpatient same-day discharge.
FDA cleared IND for FT839 dual CD19/CD38 CAR T; Phase 1/2 basket trial in autoimmune disease planned.
Preliminary SSc data: all 4 patients achieved rCRISS≥25 and mRSS improvement; no CRS/ICANS/GvHD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.